Finoriq

Finoriq insights

GLAUKOS Corp (GKOS) SEC Filings & Filing Highlights

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops. Review GKOS SEC filings, filing highlights, and disclosure activity on Finoriq.

Company Snapshot

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Company
GLAUKOS Corp (GKOS)
Ticker
GKOS
Market Cap
$10.6B
Latest Price
$179.67
Industry
Medical Devices

Open insider transactions

GLAUKOS Corp (GKOS) Recent SEC Filing Highlights

Recent SEC filings, filing events, and disclosure highlights indexed for GLAUKOS Corp (GKOS).

EventFormDate
The final voting results for each matter submitted to a vote of stockholders at the Annual Meet...The annual meeting of stockholders (the “Annual Meeting”) of Glaukos Corporation (the “Company”) was held on May 28, 2026. At the Annual Me...8-K5.072026-06-03
Investor Presentation MAY 2026 Exhibit 99.1Investor Presentation MAY 2026 Exhibit 99.18-K7.012026-05-04
Glaukos Announces First Quarter 2026 Financial ResultsGlaukos Announces First Quarter 2026 Financial Results8-K7.012026-04-29
GLAUKOS Corp: Earnings or resultsGlaukos Announces First Quarter 2026 Financial Results8-K2.022026-04-29
Investor Presentation MARCH 2026ABOUT GLAUKOS 2 © 2026 Glaukos Corporation Disclaimer All statements other than statements of historical facts included in this presentatio...8-K7.012026-03-02

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.